<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Angiotensin-converting enzyme (ACE) inhibitors have favourable effects on <z:hpo ids='HP_0000822'>hypertension</z:hpo> and diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, but persistent use may result in incomplete blockade of the renin-angiotensin system </plain></SENT>
<SENT sid="1" pm="."><plain>Long-term effects of dual blockade using the <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> <z:chebi fb="0" ids="43755">lisinopril</z:chebi> and the long-acting <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker (ARB) <z:chebi fb="0" ids="9434">telmisartan</z:chebi> on blood pressure and albumin excretion rate (AER) were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> (systolic blood pressure [SBP] &gt;or=140 mmHg or diastolic blood pressure [<z:chebi fb="4" ids="35861">DBP</z:chebi>] &gt;or=90 mmHg) and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (AER 30-300 mg/24h) received 20mg of <z:chebi fb="0" ids="43755">lisinopril</z:chebi> or 80 mg of <z:chebi fb="0" ids="9434">telmisartan</z:chebi> once a day for 24 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were then randomised to continuing treatment with the respective monotherapy or with <z:chebi fb="0" ids="43755">lisinopril</z:chebi> plus <z:chebi fb="0" ids="9434">telmisartan</z:chebi> for a further 28 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Significant (P&lt;0.001) declines in SBP (11.1 mmHg versus 10.0 mmHg), <z:chebi fb="4" ids="35861">DBP</z:chebi> (5.6 mmHg versus 5.3 mmHg) and AER (98 mg/24 h versus 80 mg/24 h) were achieved with <z:chebi fb="0" ids="43755">lisinopril</z:chebi> (n=95) or <z:chebi fb="0" ids="9434">telmisartan</z:chebi> (n=97), respectively, after 24 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequent treatment with <z:chebi fb="0" ids="43755">lisinopril</z:chebi> plus <z:chebi fb="0" ids="9434">telmisartan</z:chebi> for 28 weeks resulted in further significant reductions (P&lt;0.001) in SBP, <z:chebi fb="4" ids="35861">DBP</z:chebi> and AER compared with either monotherapy </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> treatments were well tolerated </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="43755">Lisinopril</z:chebi> plus <z:chebi fb="0" ids="9434">telmisartan</z:chebi> thus provides superior blood pressure and AER control than either monotherapy </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that use of dual blockade may provide a new approach to prevention of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
</text></document>